LivaNova (LIVN) Q3 2026 Earnings Call Transcript

LivaNova reported Q3 2026 revenue of $393.1 million, up 10% on a constant-currency basis, and adjusted diluted EPS of $1.23 versus $1.11 a year earlier. It raised full-year revenue growth guidance to 9%–10% from 8%–9% and adjusted EPS guidance to $4.40–$4.50 from $4.30–$4.40; the approximately $400 million SNIA payment shifted to Q4 2026, contributing a stated $0.03 benefit to 2026 EPS. Management also said the new oxygenator line is operational, with double-digit output expansion expected in 2027, while flagging a challenging Q4 cardiopulmonary comparison and increased investment spending.

Analysis

The quarter strengthens the operating thesis, but not all growth drivers deserve the same durability multiple. Oxygenator share gains appear supply-constrained: the new line and component access can convert unmet demand into sales, while fixed-cost absorption offers margin upside if utilization ramps. The key proof point is shipped output and backlog conversion in 2027—not stated capacity expansion alone. A slow qualification/ramp or renewed component shortages would defer both.

Epilepsy growth has a less certain mix. Better reimbursement and clinical evidence can expand procedure volumes, but realized pricing has also benefited from reduced discounting; that tailwind may fade as contracts reset. The higher Q4 comparison in cardiopulmonary and shifted OSA R&D spending also make near-term margins and growth less linear than the raised full-year outlook suggests.

OSA is meaningful longer-dated optionality, not yet a 2027 earnings driver: commercial investment precedes broad reimbursement clarity, with the new codes not effective until 2028. Management’s response-rate and addressable-market claims need independent clinical validation and payer adoption. Near term, the SNIA payment is the more immediate balance-sheet catalyst: it is a large cash use relative to reported cash. Confirm whether adjusted FCF guidance includes the settlement and how much liquidity remains afterward; the EPS benefit from timing is not recurring.

Contrarian view: the market may over-credit headline growth and pipeline optionality while underweighting cash conversion and discounting-driven pricing. Conversely, a Q4 deceleration could create an entry if oxygenator shipments and epilepsy implants remain on track.

Key Decisions for Investors

• Favor a staged LIVN long on post-results weakness rather than chasing the raise; add only as 2027 oxygenator output and backlog conversion are evidenced. Upside is share capture and operating leverage; principal downside is a delayed ramp or Q4 comp-driven estimate cuts.
• Treat epilepsy realized-price growth as a watch item, not a run-rate assumption. Track implant volumes, discounting, and reimbursement realization; a volume slowdown or reversal in realized pricing would weaken the growth thesis.
• Before increasing exposure, verify the SNIA settlement’s treatment in adjusted FCF guidance and post-payment liquidity. A materially lower cash balance or weaker FCF than the guided range would invalidate the near-term balance-sheet comfort.
• Keep OSA out of near-term earnings estimates until regulatory progress, launch readiness, and payer coverage are independently confirmed; reassess around the 2027 launch and 2028 code effectiveness.